Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress
In conclusion, we propose that PGI2 is a novel HSC regulator enriched in the endosteum that promotes HSC regenerative potential following stress.© AlphaMed Press 2021Significance StatementWe discovered prostacyclin as a novel HSC regulator enriched in endosteal bone marrow niches.Ex vivo andin vivo treatment with clinical prostacyclin analogs enhanced HSC reconstitution potential and protect HSC from stress-mediated exhaustion. These findings open new therapeutic avenues to improve HSC engraftment after autologous transplantations by shortex vivo pulse treatment with prostacyclin analogs; and limit loss of HSC and acquired bone marrow failure by protecting HSC in patients undergoing radiation or chemotherapy treatment for non-hematologic malignancies. Prostacyclin analogs are safe, used clinically for vascular diseases, and thus have potential for swift repurposing for the therapies mentioned above.
Source: Stem Cells - Category: Stem Cells Authors: Joshua Tay,
Valerie Barbier,
Falak M. Helwani,
Gareth R. Price,
Jean ‐Pierre Levesque,
Ingrid G. Winkler Tags: Tissue ‐Specific Stem Cells Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hematology | Men | Stem Cell Therapy | Stem Cells | Transplants